Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Details)

v3.5.0.2
Intangible Assets (Details) - USD ($)
Sep. 30, 2016
May 31, 2016
Business Combination Segment Allocation [Line Items]    
Liabilities assumed   $ (1,000,000)
Houston Pharmaceuticals, Inc [Member]    
Business Combination Segment Allocation [Line Items]    
Liabilities assumed $ (3,874,000)  
Moleculin LLC [Member]    
Business Combination Segment Allocation [Line Items]    
Cash 362  
Property and equipment 7,820  
Intangibles 11,128,790  
Total assets acquired 11,136,972  
Liabilities assumed (1,205,564)  
Net assets acquired/total consideration transferred $ 6,057,408